Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 4

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
Balance as of June 30,2025   17,488  $-   -  $-   752,390  $74  $107,173,418  $-  $(105,700,341) $1,473,151 

 5Table of Contents

Three Months Ended June 30,2024 Series A Convertible  Series B Convertible      Additional      Total   Preferred Stock  Preferred Stock  Common stock  Paid in  Stock  Accumulated  Stockholders'   Shares  Amount  Shares  Amount  Shares  Amount  Capital  Payable  Deficit  Equity Balance as of March 31, 2024  34,976   -   -  $-   6,236  $1  $98,403,722   301  $(94,705,852) $3,698,172 Preferred stock conversion to common stock  (17,488)  -   -   -   1   -   -   -   -   - Common stock issued for cash  -   -   -   -   3,490   -   728,503   -   -   728,503 Common stock issued for warrant exercise  -   -   -   -   25,340   2   5,289,259   -   -   5,289,261 Common stock issued for cashless warrant exercise  -   -   -       6,327   -   1,320,568   -   -   1,320,568 Fair value of vested stock options  -   -   -   -   -   -   186,590   -   -   186,590 Stock payable towards preference dividend  -   -   -   -   -       274   (274)  -   - Net loss  -   -   -   -   -   -   -   -   (2,229,153)